Zeus Hygia Lifesciences, a leading innovator in nutraceutical solutions, announced the launch of Metaberine®, the world’s first green process-enriched berberine developed using proprietary BioSOLVE Technology. Designed to overcome the limitations of conventional berberine extracts, Metaberine® delivers enhanced solubility, superior bioavailability, and a quicker onset of action all at a significantly lower dose.

The increasing prevalence of sedentary lifestyles and unhealthy dietary habits is contributing to a surge in metabolic disorders, with diabetes now affecting over 800 million adults worldwide. In recent years, GLP-1 receptor agonists have gained popularity for their dual benefits, improving glycemic control and aiding in weight management. This dual efficacy addresses the interconnected challenges of diabetes and obesity, making GLP-1 therapies a vital option. However, high costs and limited accessibility of GLP-1 treatments highlight the urgent need for more affordable, effective alternatives. Emerging oral formulations aim to enhance convenience and affordability, and Metaberine,® promising faster results at lower doses, can help meet this critical need.

Berberine: Benefits and limitations

Berberine is a naturally occurring alkaloid found in Berberine roots (Indian Barberry) and other plants. It is well-recognized for supporting metabolic health, cardiovascular function, and healthy lipid and glucose metabolism.

Despite its proven benefits, conventional berberine extracts face significant limitations:

• Poor bioavailability: Less than 2% absorption into the bloodstream
• High dosage requirement: Typically, 500–1500 mg/day in divided doses
• Delayed onset of action
• Gastrointestinal side effects: Including diarrhea, bloating, and nausea

Additionally, its low solubility slows therapeutic impact, making sustained results harder to achieve without long-term, high-dose use.

Metaberine®: A next-generation solution

“Our proprietary BioSOLVE Technology, utilizing a 100% aqueous process, produces a highly uniform, porous powder with dramatically improved solubility and bioavailability,” said Dr. Arunkanth Krishnakumar, Co-founder and CEO of Zeus Hygia. “This innovation allows Metaberine® to deliver results faster, at significantly lower doses—200 mg per day versus the 500–1500 mg typically required with regular extracts—while reducing digestive discomfort.”

Key advantages of metaberine®:

• Enhanced solubility for improved absorption and efficacy
• Lower daily dosage for better compliance
• Reduced side-effect risk due to minimal gastrointestinal impact
• Versatile applications: capsules, sachets, and more

Metaberine® is backed by proprietary bioavailability data, with ongoing human clinical trials planned. It is manufactured at Zeus Hygia, adhering to stringent quality and safety certifications.

“With the global rise in metabolic disorders such as diabetes, obesity, and cardiovascular disease, the demand for effective, natural, and safe interventions is higher than ever,” added Dr. Krishnakumar.“Metaberine® is our solution to that need—a next-generation berberine that redefines efficacy standards in the nutraceutical industry.”

Metaberine® is designed for B2B partners across the global health and wellness ecosystem, including Pharmaceutical companies, Nutraceutical and dietary supplement brands, OTC (over-the-counter) health product makers, Functional food and beverage brands, Contract manufacturers and formulators. By providing a potent, fast-acting, and cost-effective berberine solution, Zeus Hygia enables these partners to develop high-performance metabolic health products for their markets.